Safety and efficacy of nintedanib (BIBF 1120) plus pemetrexed in Japanese patients with advanced or recurrent non-small cell lung cancer (NSCLC): A phase I study

被引：0
|
作者：
Daga, Haruko
Takeda, Koji
Okada, Hideaki
Miyazaki, Masaki
Ueda, Shinya
Kaneda, Hiroyasu
Okamoto, Isamu
Yoh, Kiyotaka
Goto, Koichi
Konishi, Koichi
Sarashina, Akiko
Yagi, Nobutaka
Mera, Kiyomi
Kaiser, Rolf
Nakagawa, Kazuhiko
机构：
[1] Osaka City Gen Hosp, Dept Clin Oncol, Osaka, Japan
[2] Kinki Univ, Dept Med Oncol, Osaka, Japan
[3] Kinki Univ, Osakasayama, Japan
[4] Natl Canc Ctr Hosp East, Div Thorac Oncol, Chiba, Japan
[5] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[6] Nippon Boehringer Ingelheim Co Ltd, Med Dev Div, Tokyo, Japan
[7] Nippon Boehringer Ingelheim Co Ltd, Med Dev Div, Kobe, Hyogo, Japan
[8] Boehringer Ingelheim GmbH & Co KG, Biberach, Germany
[9] Kinki Univ, Fac Med, Higashiosaka, Osaka 577, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8056
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer
    Daga, Haruko
    Takeda, Koji
    Okada, Hideaki
    Miyazaki, Masaki
    Ueda, Shinya
    Kaneda, Hiroyasu
    Okamoto, Isamu
    Yoh, Kiyotaka
    Goto, Koichi
    Konishi, Koichi
    Sarashina, Akiko
    Tanaka, Tetsuya
    Kaiser, Rolf
    Nakagawa, Kazuhiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1225 - 1233
  • [2] Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer
    Haruko Daga
    Koji Takeda
    Hideaki Okada
    Masaki Miyazaki
    Shinya Ueda
    Hiroyasu Kaneda
    Isamu Okamoto
    Kiyotaka Yoh
    Koichi Goto
    Koichi Konishi
    Akiko Sarashina
    Tetsuya Tanaka
    Rolf Kaiser
    Kazuhiko Nakagawa
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 1225 - 1233
  • [3] A phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer (NSCLC)
    Reck, M.
    Kaiser, R.
    Eschbach, C.
    Stefanic, M.
    Gaschler-Markefski, B.
    Gatzemeier, U.
    von Pawel, J.
    ONKOLOGIE, 2010, 33 : 286 - 286
  • [4] Phase I study of oral nintedanib combined with docetaxel in previously treated Japanese patients with advanced non-small cell lung cancer (NSCLC)
    Okamoto, I.
    Miyazaki, M.
    Takeda, M.
    Azuma, K.
    Hayashi, H.
    Seto, T.
    Konishi, K.
    Sarashina, A.
    Kaiser, R.
    Nakagawa, K.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S830 - S831
  • [5] Phase II double blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients suffering from relapsed advanced non-small cell lung cancer (NSCLC)
    Reck, Martin
    Kaiser, Rolf
    Eschbach, Corinna
    Stefanic, Martin
    Love, James
    Gatzemeier, Ulrich
    von Pawel, Joachim
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (08) : S333 - S334
  • [6] Safety and efficacy of dostarlimab in patients (pts) with recurrent/advanced non-small cell lung cancer (NSCLC)
    Subramanian, J.
    Moreno, V.
    Bosch-Barrera, J.
    Pikiel, J.
    Kristeleit, R.
    Guo, W.
    Danaee, H.
    Im, E.
    Roda, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S886 - S887
  • [7] BIBF 1120 for the treatment of non-small cell lung cancer
    Reck, Martin
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2010, 19 (06) : 789 - 794
  • [8] Pemetrexed plus Cetuximab in Patients with Recurrent Non-small Cell Lung Cancer (NSCLC) A Phase I/II Study from the Hoosier Oncology Group
    Jalal, Shadia
    Waterhouse, David
    Edelman, Martin J.
    Nattam, Sreenivasa
    Ansari, Rafat
    Koneru, Karuna
    Clark, Romnee
    Richards, Arthur
    Wu, Jingwei
    Yu, Menggang
    Bottema, Brian
    White, Angela
    Hanna, Nasser
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1420 - 1424
  • [9] Tolerability of Nintedanib (BIBF 1120) in Combination with Docetaxel: A Phase 1 Study in Japanese Patients with Previously Treated Non-Small-Cell Lung Cancer
    Okamoto, Isamu
    Miyazaki, Masaki
    Takeda, Masayuki
    Terashima, Masaaki
    Azuma, Koichi
    Hayashi, Hidetoshi
    Kaneda, Hiroyasu
    Kurata, Takayasu
    Tsurutani, Junji
    Seto, Takashi
    Hirai, Fumihiko
    Konishi, Koichi
    Sarashina, Akiko
    Yagi, Nobutaka
    Kaiser, Rolf
    Nakagawa, Kazuhiko
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (02) : 346 - 352
  • [10] Efficacy and safety of nivolumab in Japanese patients with advanced or recurrent squamous non-small cell lung cancer
    Hida, Toyoaki
    Nishio, Makoto
    Nogami, Naoyuki
    Ohe, Yuichiro
    Nokihara, Hiroshi
    Sakai, Hiroshi
    Satouchi, Miyako
    Nakagawa, Kazuhiko
    Takenoyama, Mitsuhiro
    Isobe, Hiroshi
    Fujita, Shiro
    Tanaka, Hiroshi
    Minato, Koichi
    Takahashi, Toshiaki
    Maemondo, Makoto
    Takeda, Koji
    Saka, Hideo
    Goto, Koichi
    Atagi, Shinji
    Hirashima, Tomonori
    Sumiyoshi, Naoki
    Tamura, Tomohide
    CANCER SCIENCE, 2017, 108 (05) : 1000 - 1006
12345